Skip to main content
Premium Trial:

Request an Annual Quote

ABI to Help Create Proteomics Research Facility in Germany

NEW YORK (GenomeWeb News) — Applied Biosystems, Cenix Bioscience, and the Biotechnology Center of Dresden Technical University will create a joint proteomics research facility in Dresden, Germany, Cenix said yesterday.
The German federal government is supporting the facility with q €1.2 million ($1.5 million) grant through its BioChance Plus program.  
Cenix, which uses RNAi in drug research, said the two-year partnership will pursue MS-based proteomic analysis of RNAi-induced phenotypes.
The companies will work with the university to analyze gene function and drug action through cellular phenotyping, working to detect and measure effects of pharmaceutical agents that modulate gene expression on living cells.
For the alliance ABI will use its mass spec systems, protein-labeling reagents, gene-expression assays, and RNAi knockdown reagents. The company will also work on the project from its Science Center Europe in Darmstadt, Germany.
Cenix said the project will help to overcome current limits of proteome profiling by developing broad, “quantitative surveys of protein levels in RNAi and drug treated cells using antibody-independent, mass spectrometry-based analyses.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.